U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901764) titled 'MYTP01 for Immune-Mediated Diseases' on Oct. 22.
Brief Summary: The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for immune-mediated diseases (post-kidney transplantation, IgA nephropathy, etc.). The study also aims to explore whether MYTP01 may provide therapeutic benefits across these conditions by regulating shared immune and inflammatory processes. The main questions this study aims to answer are:
* Does MYTP01 provide clinical benefits and remain safe when...